Curative Biotechnology, Inc.
CUBT
$0.0115
-$0.0003-2.54%
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -74.29% | -70.31% | -- | -- | -- |
| Depreciation & Amortization | 31.15% | 48.15% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.36% | -47.63% | -- | -- | -- |
| Operating Income | 50.36% | 47.63% | -- | -- | -- |
| Income Before Tax | 44.02% | 42.02% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.02% | 42.02% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.02% | 42.02% | -- | -- | -- |
| EBIT | 50.36% | 47.63% | -- | -- | -- |
| EBITDA | 50.40% | 47.67% | -- | -- | -- |
| EPS Basic | 41.52% | 38.37% | -- | -- | -- |
| Normalized Basic EPS | 72.14% | 62.31% | -- | -- | -- |
| EPS Diluted | 41.52% | 38.37% | -- | -- | -- |
| Normalized Diluted EPS | 72.14% | 62.31% | -- | -- | -- |
| Average Basic Shares Outstanding | -3.85% | 44.03% | -- | -- | -- |
| Average Diluted Shares Outstanding | 28.29% | 44.03% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
